Amyris (NASDAQ:AMRS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.02, Fidelity Earnings reports. The company had revenue of $34.95 million during the quarter, compared to analysts’ expectations of $21.60 million.
AMRS stock traded up $0.54 during midday trading on Friday, reaching $4.52. The company had a trading volume of 2,224,200 shares, compared to its average volume of 1,905,229. The firm has a 50-day moving average price of $4.00 and a 200-day moving average price of $3.88. Amyris has a 1 year low of $1.87 and a 1 year high of $7.26. The company has a market capitalization of $431.70 million, a P/E ratio of -1.79 and a beta of 0.91.
AMRS has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Amyris in a research note on Friday, October 11th. BidaskClub raised shares of Amyris from a “sell” rating to a “hold” rating in a research note on Wednesday.
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
See Also: What is a capital gain?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.